The biotech company and Prof. Dr. Heikenwälder see common ground for joint research projects in NASH and cancer metabolism
Phenex Pharmaceuticals AG (Phenex) today announced that the company has entered into a research collaboration with the group of Prof. Dr. Mathias Heikenwälder from the DKFZ (German Cancer Research Center) in Heidelberg. Phenex has ongoing research projects in the fields of NASH (Non-alcoholic steatohepatitis), immuno-oncology and cancer metabolism and Prof. Dr. Heikenwälder is deeply interested in understanding the progression from NASH towards liver cancer, in particular. Therefore, both parties see a high overlap in their research interest which is why the join forces for the benefit of gaining deeper insights into the respective disease physiologies. Prof. Dr. Heikenwälder comments: “I am intrigued by the level of knowledge that Phenex has gained in the liver field over the last ten years and about the option to test new exploratory drugs in our animal models. This is a good example to show that we take translational research really serious. We want to see our disease knowledge contributing to the advancements of new therapies and this is exactly what Phenex does.”Dr. Claus Kremoser, CEO of Phenex, adds: “We are very excited about working together with Mathias and his group. He has a very good reputation in the field and an outstanding track record of research exactly at these crossroads between metabolism and cancer where we also position ourselves. It is just a lucky coincidence that such a good scientist is in biking distance from us, here in Heidelberg, and we are really looking forward to jointly test new drug candidates and to gain insights from his scientific work.”
Comments